NCT07316166 Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine
| NCT ID | NCT07316166 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Rhode Island Hospital |
| Condition | Postoperative Pain Management |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-01-20 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 120 participants in total. It began in 2026-01-20 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators are evaluating postoperative outcomes in patients undergoing hip replacement surgery performed with either spinal or general anesthesia, who also receive a suprainguinal fascia iliaca block using either perineural ropivacaine alone or ropivacaine combined with dexmedetomidine.
Eligibility Criteria
Inclusion Criteria: * Patients undergoing elective total hip arthroplasty * 18-80 years old * ASA 1-3 classifications Exclusion Criteria: * ASA classification of 4 or greater * Infection at the site of nerve blockade * Coagulopathy * Known allergy to study medications * Chronic opioid consumption (\>3 months) * Currently using lidocaine patches * Pre-existing neuropathy * A history of CVA * High grade atrioventricular block (cardiac conduction system impairment) * Organ dysfunction (cardiac failure, respiratory failure, end stage renal disease, hepatic dysfunction, hypoalbuminemia) * Morbid obesity (≥40 kg/m2) * Prior surgery in supra and/or infrainguinal region * Non-English-speaking participants
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07316166 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Postoperative Pain Management. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07316166 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07316166 currently recruiting?
Yes, NCT07316166 is actively recruiting participants. Contact the research team at vramanujam@brownhealth.org for enrollment information.
Where is the NCT07316166 trial being conducted?
This trial is being conducted at Providence, United States.
Who is sponsoring the NCT07316166 clinical trial?
NCT07316166 is sponsored by Rhode Island Hospital. The trial plans to enroll 120 participants.